Integra LifeSciences Reports Second Quarter 2023 Financial Results
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2023.
Second Quarter 2023 Highlights
- Second quarter revenues of
$381.3 million declined4.2% on a reported basis and declined2.7% on an organic basis compared to the prior year.
- Second quarter GAAP earnings per diluted share of
$0.05 , compared to$0.54 in the prior year; adjusted earnings per diluted share of$0.71 , compared to$0.82 in the prior year
- Appointed Lea Daniels Knight as executive vice president and CFO
Share repurchase and 2023 guidance
- Planning a
$125 million share repurchase in the third quarter
- Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of
$1.54 8 billion to$1.56 0 billion and$3.10 t o$3.18 respectively, reflecting the impact of the Boston recall and the solid performance of the underlying business
"The strong organic growth of our Codman Specialty Surgical segment and several product lines in our Tissue Technologies business demonstrate the resilience of our diversified portfolio of leading brands and technologies and strong market recovery. Excluding the impact of the Boston recall, we delivered solid, mid-single digit organic growth from the underlying business," said Jan De Witte, Integra LifeSciences’ president and chief executive officer. "We are confident in our plans for the CereLink relaunch and the restart of our Boston manufacturing facility, and we continue to advance our implant-based breast reconstruction (IBBR) PMA strategy.”
Second Quarter 2023 Consolidated Performance
Total reported revenues of
The Company reported GAAP gross margin of
Adjusted EBITDA for the second quarter of 2023 was
The Company reported GAAP net income of
Adjusted net income for the second quarter of 2023 was
Second Quarter 2023 Segment Performance
Codman Specialty Surgical (~
- Total revenues were
$271.0 million , representing reported growth of5.1% and organic growth of6.3% compared to the second quarter of 2022, due to high single-digit growth in Advanced Energy driven by CUSA capital and disposables; mid-single-digit growth in CSF management driven by Certas® Plus valves; mid-single-digit growth in Dural Access and Repair driven by Mayfield® and DuraGen®; low single-digit decline in Neuro Monitoring driven by CereLink and low double-digit growth in Instruments.
Tissue Technologies (~
- Total revenues were
$110.2 million , representing reported decline of21.2% and organic decline of19.7% compared to the second quarter of 2022, due to the impact of the lost revenue and return provision for the Boston recall which was partially offset by double digit growth from MicroMatrix®, Cytal®, MediHoney® and nerve franchise.
Key Products and Business Highlights
- Positive global demand performance across the portfolio
- Expect to restart manufacturing at the Boston facility late Q4’23 and resume commercial distribution in mid- to late Q2’24
- Relaunch of CereLink® expected late Q3’23 in international markets and late Q4’23 in the US
- Advancing IBBR PMA strategy
- Submitted clinical PMA amendment for SurgiMend®
- Completed enrollment In DuraSorb® Monofilament Mesh U.S. investigational device exemption study
- Expanded global DuraGen® portfolio with approvals in China and Japan
- Launched CUSA Lap Tip in Japan, Canada, South Africa and Israel
- Positive clinical and economic outcomes for Codman® Bactiseal® EVD Catheter from real-world evidence study in Europe
- Opened Dr. Richard E. Caruso Center of Innovation and Learning in Plainsboro, New Jersey
Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of
As of quarter end, the Company had total liquidity of approximately
Share Repurchase Program
The Company is planning for a
2023 Outlook
For the full year 2023, the Company is updating its revenue and adjusted EPS expectations to
For the third quarter 2023, the Company expects reported revenues in the range of
The Company’s guidance for the third quarter and full-year organic sales growth excludes acquisitions and divestitures, the effects of foreign currency and the year-over-year change in revenue from discontinued products. Organic growth excludes sales from the divestiture of the Company’s traditional wound care (TWC) business as of September 1, 2022, and sales from the acquisition of Surgical Innovation Associates, Inc. (SIA) through December 1, 2023. Adjusted earnings per share guidance reflects the impact of the divestiture of the TWC business, the SIA acquisition and the impact of foreign currency.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Thursday, July 27, 2023, to discuss second quarter 2023 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.
About Integra
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, charges related to the voluntary global recall of all products manufactured at the Company’s facility in Boston, Massachusetts, and income tax expense (benefit) related to non-GAAP adjustments and other items, expectations and plans with respect to strategic initiatives and product development, expectations concerning the resumption of manufacturing at the Company’s Boston, Massachusetts facility, and statements related to the repurchase of the Company’s common stock, including the timing of any purchases under the Company’s authorized stock repurchase program. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; the scope, duration and effect of additional U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; global macroeconomic and political conditions, including the war in Ukraine; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; the Company’s ability to commence any share repurchase activity, including within the anticipated timeframe; potential negative impacts resulting from environmental, social and governance matters; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2022 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted net income, adjusted earnings per diluted share, free cash flow, adjusted free cash flow conversion, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the voluntary global recall of products manufactured at the Company’s Boston, Massachusetts facility; (v) intangible asset amortization expense; and (vi) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment. The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less cash and cash equivalents.
Reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP total debt to net debt and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarter ended June 30, 2023 and 2022, and the free cash flow and adjusted free cash flow conversion for the quarter ended June 30, 2023 and 2022, appear in the financial tables in this release.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| (UNAUDITED) | |||||||
| (In thousands, except per share amounts) | |||||||
| Three Months Ended June 30, | |||||||
| 2023 | 2022 | ||||||
| Total revenues, net | 381,267 | $ | 397,815 | ||||
| Costs and expenses: | |||||||
| Cost of goods sold | 174,241 | 148,404 | |||||
| Research and development | 26,588 | 25,589 | |||||
| Selling, general and administrative | 164,908 | 160,651 | |||||
| Intangible asset amortization | 3,026 | 3,304 | |||||
| Total costs and expenses | 368,763 | 337,948 | |||||
| Operating income | 12,504 | 59,867 | |||||
| Interest income | 3,939 | 1,965 | |||||
| Interest expense | (12,464 | ) | (12,236 | ) | |||
| Gain from sale of business | — | — | |||||
| Other income, net | (155 | ) | 1,979 | ||||
| Income before income taxes | 3,824 | 51,575 | |||||
| Income tax expense | (360 | ) | 6,787 | ||||
| Net income | $ | 4,184 | $ | 44,788 | |||
| Net income per share: | |||||||
| Diluted net income per share | $ | 0.05 | $ | 0.54 | |||
| Weighted average common shares outstanding for diluted net income per share | 81,151 | 83,622 | |||||
The following table presents revenues disaggregated by the major sources for the three months ended June 30, 2023 and 2022 (amounts in thousands):
| Three Months Ended June 30, | ||||||||
| 2023 | 2022 | Change | ||||||
| Neurosurgery | 205,803 | 200,295 | 2.7 | % | ||||
| Instruments | 65,227 | 57,568 | 13.3 | % | ||||
| Total Codman Specialty Surgical | 271,030 | 257,863 | 5.1 | % | ||||
| Wound Reconstruction and Care | 91,118 | 104,894 | (13.1 | )% | ||||
| Private Label | 19,119 | 35,058 | (45.5 | )% | ||||
| Total Tissue Technologies | 110,237 | 139,952 | (21.2 | )% | ||||
| Total reported revenues | 381,267 | 397,815 | (4.2 | )% | ||||
| Impact of changes in currency exchange rates | 1,704 | — | ||||||
| Less contribution of revenues from acquisitions | (2,390 | ) | — | |||||
| Less contribution of revenues from divested products | (23 | ) | (6,371 | ) | ||||
| Less contribution of revenues from discontinued products | (1,622 | ) | (2,047 | ) | ||||
| Total organic revenues(1) | $ | 378,936 | $ | 389,397 | (2.7 | )% | ||
| Boston Revenue impact | $ | 7,374 | $ | (23,281 | ) | |||
| Total organic revenues(1) excl. Boston | $ | 386,310 | $ | 366,116 | 5.5 | % | ||
(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2023
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort (d) | OI&E(e) | Tax(f) | ||||
| Acquisition, divestiture and integration-related charges | 3,448 | 1,085 | 2,707 | (218 | ) | — | (127 | ) | — | ||
| Structural Optimization charges | 4,794 | 3,152 | 1,675 | (33 | ) | — | — | — | |||
| EU Medical Device Regulation charges | 9,278 | 859 | 3,956 | 4,463 | — | — | — | ||||
| Boston Recall | 28,051 | 28,051 | — | — | — | — | — | ||||
| Intangible asset amortization expense | 20,636 | 17,610 | — | — | 3,026 | — | — | ||||
| Estimated income tax impact from above adjustments and other items | (12,974 | ) | — | — | — | — | — | (12,974 | ) | ||
| Depreciation expense | 9,977 | — | — | — | — | — | — | ||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2022
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | ||||||
| Acquisition, divestiture and integration-related charges | (6,284 | ) | (108 | ) | (3,925 | ) | (1,059 | ) | — | (1,192 | ) | — | |
| Structural Optimization charges | 8,173 | 4,052 | 4,048 | 72 | — | — | — | ||||||
| EU Medical Device Regulation charges | 10,249 | 1,186 | 2,538 | 6,525 | — | — | — | ||||||
| Intangible asset amortization expense | 19,378 | 16,074 | — | — | 3,304 | — | — | ||||||
| Estimated income tax impact from above adjustments and other items | (7,968 | ) | — | — | — | — | — | (7,968 | ) | ||||
| Depreciation expense | 10,216 | — | — | — | — | — | — | ||||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA | |||||||
| (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Three Months Ended June 30, | |||||||
| 2023 | 2022 | ||||||
| GAAP net income | 4,184 | 44,788 | |||||
| Non-GAAP adjustments: | |||||||
| Depreciation and intangible asset amortization expense | 30,612 | 29,594 | |||||
| Other (income) expense, net | 282 | (787 | ) | ||||
| Interest expense, net | 8,525 | 10,271 | |||||
| Income tax expense (benefit) | (360 | ) | 6,787 | ||||
| Structural optimization charges | 4,794 | 8,173 | |||||
| EU Medical Device Regulation charges | 9,278 | 10,249 | |||||
| Acquisition, divestiture and integration-related charges | 3,448 | (6,284 | ) | ||||
| Boston Recall | 28,051 | — | |||||
| Total of non-GAAP adjustments | 84,630 | 58,003 | |||||
| Adjusted EBITDA | $ | 88,814 | $ | 102,791 | |||
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET | |||||||
| INCOME AND ADJUSTED EARNINGS PER SHARE | |||||||
| (UNAUDITED) | |||||||
| (In thousands, except per share amounts) | |||||||
| Three Months Ended June 30, | |||||||
| 2023 | 2022 | ||||||
| GAAP net income | 4,184 | 44,788 | |||||
| Non-GAAP adjustments: | |||||||
| Structural optimization charges | 4,794 | 8,173 | |||||
| Acquisition, divestiture and integration-related charges | 3,448 | (6,284 | ) | ||||
| EU Medical Device Regulation charges | 9,278 | 10,249 | |||||
| Boston Recall | 28,051 | — | |||||
| Intangible asset amortization expense | 20,636 | 19,378 | |||||
| Estimated income tax impact from adjustments and other items | (12,974 | ) | (7,968 | ) | |||
| Total of non-GAAP adjustments | 53,233 | 23,548 | |||||
| Adjusted net income | $ | 57,417 | $ | 68,336 | |||
| Adjusted diluted net income per share | $ | 0.71 | $ | 0.82 | |||
| Weighted average common shares outstanding for diluted net income per share | 81,151 | 83,622 | |||||
| CONDENSED BALANCE SHEET DATA | |||||
| (UNAUDITED) | |||||
| (In thousands) | |||||
| June 30, 2023 | December 31, 2022 | ||||
| Cash and cash equivalents | $ | 309,192 | $ | 456,661 | |
| Trade accounts receivable, net | 258,663 | 263,465 | |||
| Inventories, net | 354,293 | 324,583 | |||
| Current and long-term borrowing under senior credit facility | 769,460 | 771,274 | |||
| Borrowings under securitization facility | 90,800 | 104,700 | |||
| Long-term convertible securities | 568,798 | 567,341 | |||
| Stockholders' equity | $ | 1,683,160 | $ | 1,804,403 | |
| CONDENSED STATEMENT OF CASH FLOWS | |||||||
| (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Six Months Ended June 30, | |||||||
| 2023 | 2022 | ||||||
| Net cash provided by operating activities | $ | 54,435 | $ | 110,822 | |||
| Net cash used in investing activities | (29,252 | ) | (18,565 | ) | |||
| Net cash used by financing activities | (173,376 | ) | (146,612 | ) | |||
| Effect of exchange rate changes on cash and cash equivalents | 724 | (11,941 | ) | ||||
| Net decrease in cash and cash equivalents | $ | (147,469 | ) | $ | (66,296 | ) | |
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO | ||||||
| MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION | ||||||
| (UNAUDITED) | ||||||
| (In thousands) | ||||||
| Three Months Ended June 30, | ||||||
| 2023 | 2022 | |||||
| Net cash provided by operating activities | 28,278 | $ | 66,484 | |||
| Purchases of property and equipment | (15,646 | ) | $ | (9,405 | ) | |
| Free cash flow | 12,632 | 57,079 | ||||
| Adjusted net income(1) | $ | 57,417 | $ | 68,335 | ||
| Adjusted free cash flow conversion | 22.0 | % | 83.5 | % | ||
| Twelve Months Ended June 30, | ||||||
| 2023 | 2022 | |||||
| Net cash provided by operating activities | 208,079 | $ | 262,887 | |||
| Purchases of property and equipment | (52,963 | ) | (53,444 | ) | ||
| Free cash flow | 155,116 | 209,443 | ||||
| Adjusted net income(1) | 268,667 | $ | 275,548 | |||
| Adjusted free cash flow conversion | 57.7 | % | 76.0 | % | ||
(1) Adjusted net income for quarters ended June 30, 2023 and 2022 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION | ||||||
| (UNAUDITED) | ||||||
| (In thousands) | ||||||
| June 30, 2023 | December 31, 2022 | |||||
| Short-term borrowings under senior credit facility | $ | 4,844 | $ | 38,125 | ||
| Long-term borrowings under senior credit facility | 764,616 | 733,149 | ||||
| Borrowings under securitization facility | 90,800 | 104,700 | ||||
| Long-term convertible securities | 568,798 | 567,341 | ||||
| Deferred financing costs netted in the above | 11,742 | 11,385 | ||||
| Cash & Cash Equivalents | (309,192 | ) | (456,661 | ) | ||
| Net Debt | $ | 1,131,608 | $ | 998,039 | ||
